Ameriprise
EOLS icon

Ameriprise’s Evolus EOLS Stock Holding History

Ameriprise’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$226K Buy
32,545
+1,910
+6% +$11.3K ﹤0.01% 3926
2026
Q1 		$126K Sell
30,635
-23,635
-44% -$115K ﹤0.01% 3938
2025
Q4 		$361K Sell
54,270
-3,062
-5% -$20.7K ﹤0.01% 3743
2025
Q3 		$352K Sell
57,332
-506
-0.9% -$3.95K ﹤0.01% 3737
2025
Q2 		$533K Sell
57,838
-7,977
-12% -$81.6K ﹤0.01% 3508
2025
Q1 		$792K Sell
65,815
-14,631
-18% -$191K ﹤0.01% 3300
2024
Q4 		$888K Buy
80,446
+8,214
+11% +$116K ﹤0.01% 3295
2024
Q3 		$1.17M Sell
72,232
-10,992
-13% -$154K ﹤0.01% 3154
2024
Q2 		$903K Sell
83,224
-10,167
-11% -$125K ﹤0.01% 3193
2024
Q1 		$1.31M Sell
93,391
-17,748
-16% -$231K ﹤0.01% 3064
2023
Q4 		$1.17M Sell
111,139
-13,317
-11% -$119K ﹤0.01% 3124
2023
Q3 		$1.14M Buy
124,456
+93,185
+298% +$836K ﹤0.01% 3079
2023
Q2 		$227K Buy
31,271
+340
+1% +$2.93K ﹤0.01% 3695
2023
Q1 		$262K Sell
30,931
-1,300
-4% -$11.8K ﹤0.01% 3652
2022
Q4 		$242K Buy
32,231
+990
+3% +$7.67K ﹤0.01% 3658
2022
Q3 		$251K Sell
31,241
-380
-1% -$4.03K ﹤0.01% 3640
2022
Q2 		$367K Sell
31,621
-1,090
-3% -$12.9K ﹤0.01% 3499
2022
Q1 		$367K Buy
32,711
+720
+2% +$6.14K ﹤0.01% 3579
2021
Q4 		$208K Sell
31,991
-3,510
-10% -$24.1K ﹤0.01% 3781
2021
Q3 		$271K Sell
35,501
-1,723
-5% -$17.8K ﹤0.01% 3612
2021
Q2 		$471K Buy
37,224
+3,350
+10% +$36.8K ﹤0.01% 3477
2021
Q1 		$440K Sell
33,874
-300
-0.9% -$2.77K ﹤0.01% 3456
2020
Q4 		$115K Sell
34,174
-3,197
-9% -$12K ﹤0.01% 3677
2020
Q3 		$146K Sell
37,371
-2,530
-6% -$9.24K ﹤0.01% 3601
2020
Q2 		$211K Buy
39,901
+2,485
+7% +$11.4K ﹤0.01% 3479
2020
Q1 		$155K Sell
37,416
-639
-2% -$5.42K ﹤0.01% 3479
2019
Q4 		$463K Sell
38,055
-2,927
-7% -$41.3K ﹤0.01% 3358
2019
Q3 		$640K Buy
40,982
+1,475
+4% +$24.2K ﹤0.01% 3213
2019
Q2 		$578K Sell
39,507
-226
-0.6% -$4.48K ﹤0.01% 3276
2019
Q1 		$897K Buy
+39,733
New +$859K ﹤0.01% 3089

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Ameriprise's EOLS Position: Q2 2026 in Review

Ameriprise increased its Evolus (EOLS) stake by 6.2% in Q2 2026, buying an estimated $11.3K and bringing the position to 32,545 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

Ameriprise first reported a position in EOLS in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.31M in Q1 2024. 159 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

  • Ameriprise held 32,545 shares of Evolus worth $226K as of Q2 2026.
  • Ameriprise bought 1,910 Evolus shares in Q2 2026, an estimated $11.3K.
  • Evolus made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3926 holding.
  • Ameriprise first reported a position in Evolus in Q1 2019 and has held it in 30 quarters since.
  • Ameriprise's Evolus position peaked at $1.31M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.